NJ State Employees Deferred Compensation Plan maintained its position in shares of Geron Corporation (NASDAQ:GERN) during the second quarter, according to its most recent disclosure with the SEC. The firm owned 300,000 shares of the biopharmaceutical company’s stock at the end of the second quarter. NJ State Employees Deferred Compensation Plan owned about 0.19% of Geron Corporation worth $831,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of GERN. Russell Investments Group Ltd. acquired a new position in shares of Geron Corporation during the second quarter worth approximately $114,000. Tudor Investment Corp ET AL increased its position in shares of Geron Corporation by 12.1% in the first quarter. Tudor Investment Corp ET AL now owns 52,369 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 5,669 shares in the last quarter. Raymond James Financial Services Advisors Inc. increased its position in shares of Geron Corporation by 31.0% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 57,056 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 13,500 shares in the last quarter. Bank of America Corp DE increased its position in shares of Geron Corporation by 26.5% in the first quarter. Bank of America Corp DE now owns 65,403 shares of the biopharmaceutical company’s stock worth $148,000 after buying an additional 13,698 shares in the last quarter. Finally, American International Group Inc. increased its position in shares of Geron Corporation by 7.1% in the first quarter. American International Group Inc. now owns 92,964 shares of the biopharmaceutical company’s stock worth $211,000 after buying an additional 6,140 shares in the last quarter. 38.16% of the stock is currently owned by institutional investors and hedge funds.

Shares of Geron Corporation (NASDAQ:GERN) opened at 2.22 on Monday. The stock’s market cap is $353.37 million. Geron Corporation has a 1-year low of $1.81 and a 1-year high of $3.15. The company’s 50-day moving average is $2.80 and its 200 day moving average is $2.48.

TRADEMARK VIOLATION WARNING: This piece was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://www.dailypolitical.com/2017/08/07/nj-state-employees-deferred-compensation-plan-has-831000-stake-in-geron-corporation-nasdaqgern.html.

A number of equities analysts have recently commented on GERN shares. Zacks Investment Research raised shares of Geron Corporation from a “hold” rating to a “buy” rating and set a $3.00 target price on the stock in a research note on Wednesday, May 31st. FBR & Co reissued a “buy” rating on shares of Geron Corporation in a research note on Tuesday, July 4th. Stifel Nicolaus reissued a “hold” rating and issued a $2.50 target price on shares of Geron Corporation in a research note on Wednesday, April 12th. Piper Jaffray Companies reissued an “overweight” rating and issued a $5.00 target price on shares of Geron Corporation in a research note on Wednesday, April 12th. Finally, BidaskClub downgraded shares of Geron Corporation from a “hold” rating to a “sell” rating in a research note on Saturday. One investment analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $3.88.

Geron Corporation Company Profile

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity.

Institutional Ownership by Quarter for Geron Corporation (NASDAQ:GERN)

Receive News & Ratings for Geron Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron Corporation and related companies with MarketBeat.com's FREE daily email newsletter.